10
NEWS
Control-iQ and
young T1Ds
Researchers from Italy have found encouraging
results from their review of the current
evidence on the psychological, safety, and
exercise-related outcomes of the t:slim X2
insulin pump with Control-IQ technology from
Tandem Diabetes Care in children, adolescents,
and young adults with Type 1 diabetes.
The review found that Control-IQ
technology is not only safe but also effective in
improving key quality-of-life measures:
• Significant reduction in fear of
hypoglycemia for young people and their
parents
• Decreased diabetes-related distress
• Improved sleep quality for both patients
and caregivers
• Lower risk of exercise-related
hypoglycemia
The review concluded that "this secondgeneration
automated insulin delivery system
reduces the burden of diabetes. It properly
addresses most psychological issues in
children, adolescents, and young adults with
Type 1 diabetes."
GPs to prescribe
Mounjaro
As reported by the BBC, prescriptions for Mounjaro jabs, to
help people lose weight, are now available at GP surgeries
in England - but only for those who meet very strict
criteria.
NHS England says while the long-term plan is for the
jabs to be more widely available, a staggered approach is
needed to reach those most at need, manage GPs' workload
and NHS resources. GPs say they don't have enough
doctors to deal with demand for the medicine and are
urging people not to approach their local surgery unless
they are eligible.
According to NHS England, the first group of patients
who will be able to get the jab from their GP or a
community clinic, will be those most in need.
This is defined as people with:
• a BMI of 40 or over (or 37.5 if from a minority ethnic
background)
• and four out of five of the following conditions: type
2 diabetes, high blood pressure, heart and vascular
disease, high cholesterol and obstructive sleep apnoea
However, prescriptions for the drug will not necessarily
be available from all local GPs. In some cases, they will
come from other primary care services. NHS England says
people should check their integrated care board (ICB)
website for more information.
According to the Pharmaceutical Journal, NHS England
is also reportedly looking to tender for a contract to
provide behavioural change support for patients prescribed
tirzepatide (i.e. Mounjaro) for weight management in
primary care. This 'wrap around care' for patients using
tirzepatide would comprise of two distinct elements:
clinical support - including safe prescribing, monitoring
of comorbidities and management of potential drug
interactions - and behavioural support to drive sustainable
lifestyle change through structured interventions. Both
services would be delivered under one national provider
framework.
MiniMed wider range
In mid-July Medtronic announced that it has received CE Mark to expand
indications for the MiniMed 780G system. This makes the system accessible
to a wider range of individuals, including children as young as 2 years old,
pregnant women, and those living with Type 2 insulin-requiring diabetes. This
CE Mark expansion of indications is backed by robust clinical data and highlights
Medtronic's commitment to improving outcomes and quality of life for people
living with diabetes at every stage of life.
www.medtronic-diabetes.co.uk